Spero Therapeutics (SPRO) Change in Acquisitions & Divestments (2018 - 2022)

Spero Therapeutics (SPRO) has 5 years of Change in Acquisitions & Divestments data on file, last reported at $49.9 million in Q2 2022.

• Quarterly Change in Acquisitions & Divestments rose 143.27% year-over-year to $49.9 million in Q2 2022, while the trailing twelve-month figure through Mar 2023 was $49.9 million (down 11.66% YoY) and the FY2022 annual result came in at $60.8 million, up 17.9% from the prior year.
• Change in Acquisitions & Divestments advanced to $49.9 million in Q2 2022, from $10.9 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $50.6 million in Q1 2019 to a low of $2.0 million in Q4 2020.
• A 5-year average of $20.7 million and a median of $18.3 million in 2020 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2020 — Change in Acquisitions & Divestments sank 85.61% — and 2021, when it soared 351.2%.
• Tracing SPRO's Change in Acquisitions & Divestments over 5 years: stood at $35.5 million in 2018, then sank by 76.03% to $8.5 million in 2019, then plunged by 76.47% to $2.0 million in 2020, then jumped by 250.0% to $7.0 million in 2021, then soared by 612.44% to $49.9 million in 2022.
• The last three Change in Acquisitions & Divestments figures came in at $49.9 million (Q2 2022), $10.9 million (Q1 2022), and $7.0 million (Q4 2021), per Business Quant data.